Skip to main content
FDCT
OTC Technology

FDCTech Restates Q2 2025 Financials, Reveals $15.86M Asset Reduction & Material Control Weaknesses

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Technology
Sentiment info
Negative
Importance info
9
Price
$0.061
Mkt Cap
$25.808M
52W Low
$0.001
52W High
$0.115
52W Position
Off High info
47% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

Summary

FDCTech restated its Q2 2025 financials, revealing significant reductions in assets and equity due to accounting errors and material weaknesses in internal controls, following a non-reliance notice.


Key Events · Corporate Governance and Compliance · FDCT

  • Q2 2025 Financial Restatement

    The company restated its unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, and comparative periods, due to identified errors.

  • Non-Reliance on Prior Financials

    The Board concluded that previously issued financials for multiple periods (Q1, Q2, Q3 2025, Q1 2026, FY 2024, FY 2025) should no longer be relied upon, as disclosed in a concurrent 8-K.

  • Significant Financial Adjustments

    Total assets decreased by $15.86 million and total stockholders' equity decreased by $7.98 million as of June 30, 2025, compared to previously reported figures. Cash and restricted cash combined also saw a $7.13 million reduction.

  • Material Weaknesses in Internal Controls

    The company identified material weaknesses related to subscription receivable classification, stock issuance tracking, restricted cash presentation, and noncontrolling interest allocation.


Analysis · FDCT · Technology

This filing is highly important because it details the restatement of Q2 2025 financial results, which were previously deemed unreliable. The restatements reveal substantial accounting errors, leading to a $15.86 million reduction in total assets and a $7.98 million decrease in total equity as of June 30, 2025. These adjustments, particularly the reclassification of a significant subscription receivable to contra-equity and the proper segregation of client funds, indicate fundamental issues with financial reporting accuracy. The disclosure of multiple material weaknesses in internal controls further underscores the severity of these problems, suggesting systemic deficiencies that could impact future financial reliability. This is part of a broader series of restatements and non-reliance notices, signaling a critical period for the company's financial integrity and investor confidence.

At the time of this filing, FDCT was trading at $0.06 on OTC in the Technology sector, with a market capitalization of approximately $25.8M. The 52-week trading range was $0.00 to $0.12. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FDCT - Latest Insights

FDCT
Jun 23, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.034
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info
FDCT
Jun 23, 2026, 4:37 PM EDT
Filing Type: 10-K/A
Importance Score:
8
Price at Filing: $0.034
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info
FDCT
Jun 08, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.061
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info
FDCT
Jun 08, 2026, 5:30 PM EDT
Filing Type: 10-Q/A
Importance Score:
9
Price at Filing: $0.061
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info
FDCT
Jun 08, 2026, 5:29 PM EDT
Filing Type: 10-K/A
Importance Score:
9
Price at Filing: $0.061
Real-time Price: $0.030 info
Change: Reverse Stock Split info
Market Cap: $12.693M info